GlaxoSmithKline (GSK) and the University of North Carolina, Chapel Hill, are partnering to find a cure for HIV, the virus that causes AIDS.

Each has pledged significant resources to a new company, named Qura Therapeutics, with the goal of curing HIV.

According to BuzzFeed News, GSK has pledged $20 million over five years and roughly 10 of its scientists, while the University of North Carolina will contribute 40 researchers and access to resources located on its medical campus.

The pairing is unusual because it does not revolve around any specific invention or technology.

“This sounds very open-ended,” said Kenneth Kaitin, director of the Tufts Center for the Study of Drug Development. “And I think this part of it is kind of usual.”

GSK and UNC-Chapel Hill have long been involved in HIV/AIDS research.